Jim is the Cofounder / CEO of Nosis Biological Sciences, Inc. where he focuses on the mission to deliver targeted genetic medicines to treat otherwise untreatable complex diseases.

Jim co-founded Nosis after working for more than 15 years at the intersection of data science and healthcare innovation. Most recently, Jim was Head of Oncology Products at Natera (NASDAQ: NTRA) where he was responsible for the product roadmap, product definition, prioritization, technical leadership, and strategic vision for Natera’s Oncology product portfolio. Jim’s products included Signatera, the leading Molecular Residual Disease test for early relapse detection in solid tumors, as well as other NGS-related tissue and liquid biopsy profiling products and technologies. Jim’s products are actively used today by thousands of medical oncologists, by tens of thousands of patients, in dozens of clinical trials, and have been published in NEJM, Nature, and JAMA Oncology.

Prior to Natera, Jim spent four years with Flatiron Health (acquired by Roche in 2018 for $2 billion). At Flatiron, Jim served as Director of Product and Operations holding responsibility for product strategy, budgeting, roadmap, product execution, and operations. In this position, Jim concepted, built, and launched a suite of enterprise real world data products that are used today by thousands of medical oncologists, hundreds of researchers, and in partnership with multiple National Cancer Institute-Designated Academic Medical Centers of Excellence.

Jim received his MBA in Health Care Management from The Wharton School at the University of Pennsylvania. He earned his MS in Computational & Mathematical Engineering from Stanford University and his BS in Engineering Physics from the Colorado School of Mines.

Dr. Seth Myers is the Cofounder / Chief  Technology Officer of Nosis Biological Sciences, Inc. where he focuses on the mission to deliver  targeted genetic medicines to treat otherwise untreatable complex diseases.

Seth co-founded Nosis after working at the cutting edge of deep learning, graph neural networks, and natural language processing for over a decade. Prior to co-founding Nosis, Seth worked as the Vice President of Product & Head of Data Science at DemandBase, a late stage venture-backed technology firm in San Francisco, CA. At Demandbase, Seth and his team developed a best in class machine learning platform that is now used by thousands of customers processing billions of transactions every day.

Prior to DemandBase, Seth was the Chief Scientist for Spiderbook, a machine learning startup focused on organizing the world’s information on how companies collaborate. Seth’s work led to the successful acquisition of Spiderbook by DemandBase in 2016. Seth is a prolific researcher whose published work on machine learning has been cited over 6,000 times. Seth has developed multiple technologies in deep learning, broader machine learning, and generative AI.

At Nosis, Seth leads development of the Nosis cell-targeting platform where he has concepted, designed, and implemented over 10 proprietary innovations. Seth is also responsible for recruiting and managing a team of best-in-class interdisciplinary scientists from both academic and industry backgrounds.

Seth received his PhD in Computational Mathematics from Stanford University. Seth earned his BA from Northwestern University, where he triple majored in Math, Physics, and Integrated Science.

Dr. Chad Miller is the Cofounder / Head of Research of Nosis Biological Sciences, Inc. where he focuses on the mission to deliver  targeted genetic medicines to treat otherwise untreatable complex diseases.

Before cofounding Nosis, Chad worked at the frontier of protein design at Institute for Protein Design (IPD) at the University of Washington under David Baker. Chad led multiple projects at the interface of protein design and immunology, using de novo protein scaffolds to enable a new class of vaccines. This work was funded by the Bill and Melinda Gates Foundation and Amgen.

Prior to joining the IPD, Chad completed a doctorate in Pharmacology at Yale University focusing on cell signaling specificity and rational engineering of kinases. Chad was a recipient of the HHMI translational fellowship and was also selected for the inaugural class of Yale-Canaan Venture Fellows. He has published over 20 papers contributing to mathematical and computational biochemistry, cell signaling, and immunological ligand design. His h-index is 16, and his Erdős number is 2.

At Nosis, Chad overseas all wet lab capabilities, including multiple high-throughput biochemical discovery and validation assays. Chad has expanded the laboratory team by hiring exceptional researchers from academia and industry across multiple disciplines. He is responsible for enabling and coordinating the chemistry, biochemistry, cell biology, and translational functions at Nosis.

Prior to his doctoral studies, Chad earned an M.S. in Chemistry and a B.A. with Honors from Youngstown State University, where he served as Presidentof the Student Government Association.

Dr. Chad Miller is the Cofounder / Head of Research of Nosis Biological Sciences, Inc. where he focuses on the mission to deliver  targeted genetic medicines to treat otherwise untreatable complex diseases.

Before cofounding Nosis, Chad worked at the frontier of protein design at Institute for Protein Design (IPD) at the University of Washington under David Baker. Chad led multiple projects at the interface of protein design and immunology, using de novo protein scaffolds to enable a new class of vaccines. This work was funded by the Bill and Melinda Gates Foundation and Amgen.

Prior to joining the IPD, Chad completed a doctorate in Pharmacology at Yale University focusing on cell signaling specificity and rational engineering of kinases. Chad was a recipient of the HHMI translational fellowship and was also selected for the inaugural class of Yale-Canaan Venture Fellows. He has published over 20 papers contributing to mathematical and computational biochemistry, cell signaling, and immunological ligand design. His h-index is 16, and his Erdős number is 2.

At Nosis, Chad overseas all wet lab capabilities, including multiple high-throughput biochemical discovery and validation assays. Chad has expanded the laboratory team by hiring exceptional researchers from academia and industry across multiple disciplines. He is responsible for enabling and coordinating the chemistry, biochemistry, cell biology, and translational functions at Nosis.

Prior to his doctoral studies, Chad earned an M.S. in Chemistry and a B.A. with Honors from Youngstown State University, where he served as Presidentof the Student Government Association.